Over the past few years, the rate of incidence of cystic fibrosis (CF) has registered a sharp rise. According to the U.S. Cystic Fibrosis Patient registry, over 70,000 people worldwide are suffering from the disease and about 1,000 new cases of CF are diagnosed every year in U.S. alone. Advanced treatments have augmented lives of people with CF. However, there is still no cure. These factors are creating ample opportunities for the development of cystic fibrosis therapeutics.
What is Cystic Fibrosis (CF)?
Cystic fibrosis refers to a genetic disease that affects lungs and other secretory glands such as liver, kidneys, pancreas, and intestines. It is caused by alterations in both copies of gene for protein involving cystic fibrosis transmembrane conductance regulator (CFTR). CF often results in abnormal secretions that lead to mucus buildup. This buildup leads to improper functioning of the affected organ, which is usually diagnosed by genetic testing and a sweat test.
FDA Approves Relizorb for Children with CF
The severity of symptoms of CF differs widely among different age groups. Therapeutics used are different for children and adults. However, players are trying to develop therapeutics and devices that can be used by all age groups. For instance, in July 2017, Alcresta Therapeutics announced that its product, Relizorb, is now available to children as well. The U.S. Food and Drug Administration (FDA) gave the green signal to using the device in adults in 2015. It has now approved it for children as young as five. Relizorb is a cartridge containing enzymes that help in breaking down fats into tube-feeding formulas.
Market Insights
According to Grand View Research Inc., the global cystic fibrosis therapeutics market is estimated to a valuation of USD 13.9 billion by 2025. Rising prevalence of CF along with increasing awareness regarding availability of therapies is expected to be one of the primary growth stimulants of the market. Players in the market are increasingly collaborating with nonprofit organizations to develop novel therapeutics for treatment of CF. Tremendous advancements in research and care due to these collaborations are likely to provide a fillip to the market.
Despite favorable reimbursement policies, high cost involved in treating CF can impede market growth. Moreover, CF is a complex disease and its complexity is increasing with time. This is acting as a key roadblock to the growth of the market. Influx of generic drugs, coupled with patent expiry of blockbuster drugs, is expected to adversely affect overall revenue generation of the market.
Some of the key companies in the market are F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; and Merck & Co., Inc.
In-Depth research report on Cystic Fibrosis (CF) Therapeutics Market:
No comments:
Post a Comment